Company Overview of Cellective Therapeutics, Inc.
As of October 14, 2005, Cellective Therapeutics, Inc. was acquired by MedImmune, LLC. Cellective Therapeutics, Inc., a drug development company, engages in discovering, developing, and commercializing monoclonal antibodies for the treatment of B-cell cancers and autoimmune diseases. Its products include monoclonal antibodies that target the B-cell antigens CD19, CD20, and CD22 are in preclinical stage programs. The company was founded in 2003 and is based in Gaithersburg, Maryland. It also has offices in North Carolina and Maryland.
35 West Watkins Mill Road
Gaithersburg, MD 20878
Founded in 2003
Key Executives for Cellective Therapeutics, Inc.
Cellective Therapeutics, Inc. does not have any Key Executives recorded.
Similar Private Companies By Industry
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
|7 Oaks Pharmaceutical Corp.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
To contact Cellective Therapeutics, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.